Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT06486779
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06470048
- Locations
- 🇺🇸
Clinical Res Of W Florida, Clearwater, Florida, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
🇹🇷Novartis Investigative Site, Istanbul, Turkey
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06462469
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
Completed
- Conditions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT06460324
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT06444087
- Locations
- 🇫🇷
Novartis Investigative Site, Bordeaux Cedex, France
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06444113
- Locations
- 🇺🇸
UCSF ., San Francisco, California, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 315
- Registration Number
- NCT06439082
- Locations
- 🇺🇸
WCG Sonar Clinical Research, Riverdale, Georgia, United States
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06431763
- Locations
- 🇩🇪
Novartis Investigative Site, Voelklingen, Germany
Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06431750
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT06427811
© Copyright 2024. All Rights Reserved by MedPath